公开(公告)号：US11833215B2

公开(公告)日：2023-12-05

申请号：US16893359

申请日：2020-06-04

Applicant: Novartis AG

Inventor： Tinya Abrams ,  Steven Bruce Cohen ,  Dylan Daniel ,  Catrin Finner ,  Bernhard Hubert Geierstanger ,  Thomas Huber ,  William Mallet ,  Matthew John Meyer ,  Weijia Ou ,  Siew Ho Schleyer ,  Kathrin Ulrike Tissot-Daguette

IPC: C07K16/00 ,  A61K39/00 ,  A61K47/68 ,  C07K16/28 ,  A61K51/10 ,  A61K49/00 ,  A61P35/02 ,  A61K39/395

CPC classification number: A61K47/6803 ,  A61K39/39558 ,  A61K47/6849 ,  A61K49/00 ,  A61K51/103 ,  A61K51/1093 ,  A61P35/02 ,  C07K16/2803 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/77 ,  C07K2317/92

Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

公开(公告)号：US20230052970A1

公开(公告)日：2023-02-16

申请号：US17937488

申请日：2022-10-03

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Hilmar Erhard Ebersbach ,  David Glass ,  Thomas Huber ,  Julia Jascur ,  Carl H. June ,  Jihyun Lee ,  Joan Mannick ,  Michael C. Milone ,  Leon Murphy ,  Avery D. Posey ,  Huijuan Song ,  Yongqiang Wang ,  Lai Wei ,  Qilong Wu ,  Qiumei Yang ,  Jiquan Zhang

IPC: C07K16/28 ,  A61K35/17 ,  C07K16/30 ,  C07K14/705 ,  A61P35/02 ,  A61P35/00 ,  A61K48/00 ,  C07K14/725 ,  C12N15/86

Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.

公开(公告)号：US20210139595A1

公开(公告)日：2021-05-13

申请号：US17083211

申请日：2020-10-28

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Hilmar Erhard Ebersbach ,  Thomas Huber ,  Julia Jascur ,  Celeste Richardson ,  Reshma Singh ,  Huijuan Song ,  Qilong Wu ,  Jiquan Zhang

IPC: C07K16/28 ,  A61K39/395 ,  A61K31/436 ,  C07K14/725 ,  C07K14/705 ,  C07K16/30 ,  A61K35/28 ,  A61K31/711 ,  A61K38/17 ,  A61K45/06 ,  C07K14/715 ,  A61K48/00

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.

公开(公告)号：US20200223917A1

公开(公告)日：2020-07-16

申请号：US16588063

申请日：2019-09-30

Applicant: Novartis AG ,  DANA-FARBER CANCER INSTITUTE, INC. ,  Children's Medical Center Corporation

Inventor： Catherine Anne Sabatos-Peyton ,  Barbara Brannetti ,  Alan S. Harris ,  Thomas Huber ,  Thomas Pietzonka ,  Jennifer Marie Mataraza ,  Walter A. Blattler ,  Daniel J. Hicklin ,  Maximiliano Vasquez ,  Rosemarie H. DeKruyff ,  Dale T. Umetsu ,  Gordon James Freeman ,  Tiancen Hu ,  John A. Taraszka ,  Fangmin Xu

IPC: C07K16/28 ,  G01N33/574 ,  A61K39/395 ,  A61K45/06 ,  G01N33/68

Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.

公开(公告)号：US10117953B2

公开(公告)日：2018-11-06

申请号：US15284444

申请日：2016-10-03

Applicant: Novartis AG

Inventor： Tinya Abrams ,  Steven Bruce Cohen ,  Christie P. Fanton ,  Thomas Huber ,  Kathy Miller ,  Siew Ho Schleyer ,  Kathrin Ulrike Tissot-Daguette ,  Catrin Finner

IPC: A61K47/48 ,  A61K47/68 ,  A61K45/06 ,  C07K16/28 ,  A61K31/537 ,  A61K47/12 ,  A61K47/26 ,  A61K9/19 ,  A61K9/00 ,  A61K49/00 ,  A61K51/10 ,  C07K16/32 ,  A61K39/00

Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

公开(公告)号：US09777061B2

公开(公告)日：2017-10-03

申请号：US14805236

申请日：2015-07-21

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Hilmar Erhard Ebersbach ,  Thomas Huber ,  Julia Jascur ,  Celeste Richardson ,  Reshma Singh ,  Huijuan Song ,  Qilong Wu ,  Jiquan Zhang

IPC: C12N5/071 ,  C12N5/16 ,  C07K16/28 ,  C07K14/705 ,  A61K39/395 ,  A61K31/436 ,  C07K14/725 ,  C07K16/30 ,  A61K38/17 ,  A61K45/06 ,  C07K14/715 ,  A61K48/00 ,  A61K35/28 ,  A61K39/00 ,  A61K38/00

CPC classification number: C07K16/2851 ,  A61K31/436 ,  A61K31/711 ,  A61K35/28 ,  A61K38/00 ,  A61K38/1774 ,  A61K38/1793 ,  A61K39/39558 ,  A61K45/06 ,  A61K48/00 ,  A61K2039/505 ,  A61K2039/5156 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/7056 ,  C07K14/70578 ,  C07K14/7151 ,  C07K16/2803 ,  C07K16/30 ,  C07K16/3061 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2319/70 ,  A61K2300/00

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.